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Abstract
In the present study, the antimicrobial susceptibilities of 97 Escherichia coli isolates from birds, and 100 clinical isolates from blood
cultures, were determined by disk diffusion. The wild-type distributions were deﬁned by the normalized resistance interpretation
method. It is shown that the avian and clinical inhibition zone diameter distributions of wild-type E. coli are indistinguishable.
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Introduction
Antimicrobial susceptibility testing (AST) is an important tool
that guides clinicians in prescribing appropriate treatment
regimens to patients. It is also the cornerstone of antimicro-
bial resistance surveillance. Regardless of the method
employed, phenotypic susceptibility testing requires interpre-
tive criteria (breakpoints) that will convert the test result
(e.g. Minimum Inhibitory Concentration (MIC) value or zone
diameter) into a qualitative value, in order to allow categori-
zation of isolates as susceptible, indeterminant (or intermedi-
ate), or resistant. These qualitative values can be based
either on clinical criteria to guide therapy (clinical break-
points), or on microbiological criteria to distinguish between
isolates with and without acquired phenotypically detectable
resistance mechanisms (epidemiological cut-off values
(ECOFFs)), as introduced by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)[1].
In Europe, EUCAST is coordinating the work of national
breakpoint committees [2]. It has a mandate to harmonize
susceptibility testing methods and clinical breakpoints within
Europe and to determine clinical breakpoints for new anti-
microbial agents as part of the regulatory process for
approval of new drugs in Europe [3]. Apart from determining
clinical breakpoints, EUCAST has introduced the concept of
ECOFFs. These are determined on the basis of large MIC
distributions and separate MIC data for wild-type organisms,
i.e. organisms without phenotypically detectable resistance
mechanisms, from non-wild-type organisms with acquired
resistance. The MIC distributions and ECOFFs are freely
available at http://www.eucast.org.
The ECOFF value can be described as the highest MIC
value of the wild-type distribution, and is expressed as
WT £ X mg/L [1,4]. Thus, by application of an ECOFF to a
bacterial MIC distribution, microorganisms may be classiﬁed
as either wild-type or non-wild-type. ECOFFs, whether
derived from MIC or inhibition zone diameter (IZD) distribu-
tions, have become valuable tools for resistance surveillance,
and are being used by several organizations and institutions
for the phenotypic screening of bacteria for resistance.
The exact procedure for determining ECOFFs from MIC
distributions has been described in previous reports [1,5]. In
order to facilitate the deﬁnition of the wild-type population
in IZD distributions, the normalized resistance interpretation
(NRI) method was developed by Kronvall et al. in 2003 [6].
This method has been employed to deﬁne wild-type distribu-
tions in bacterial species of various origin [7–10], and has
also proven to be a useful tool for the validation and inter-
laboratory comparison of AST methods [8,11].
The Gram-negative bacterium Escherichia coli constitutes
an important part of the normal gastrointestinal microbiota
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in humans as well as animals. In the present study,
phenotypic resistance to 16 antimicrobial agents in E. coli
isolates from the gut ﬂora of arctic birds and from
septicaemia cases in humans has been compared. It is shown
that the NRI method can be used to establish NRI-derived
cut-off values in both clinical and non-clinical populations of
E. coli, and that these values correlate well.
Materials and Methods
In 2005, the Swedish Polar Research Secretariat organized
an expedition to the Arctic to study arctic ecology. During
this expedition, cloacal swabs were collected from arctic
birds in three different geographical regions: northern Sibe-
ria, Alaska, and Greenland. The faecal samples were trans-
ported in a swab-transport system (Copan; Difco,
Lawrence, KS, USA) to an on-site laboratory. Upon arrival,
they were cultured overnight on ‘Enterobacteriaceae selec-
tive medium’ [12] at 37C, and single colonies were iso-
lated on blood agar plates (Difco). One isolate of E. coli
(Gram-negative, H2S-negative, and indole-positive) was
selected from each sample and stored at )70C for further
analysis.
In the present study, 97 avian E. coli isolates, and 100
E. coli isolates from blood cultures performed at Va¨xjo¨ Hos-
pital in 2004–2005, were used for comparison, together with
25 identical copies of the reference strain E. coli ATCC
25922. A laboratory technician, otherwise not involved in
the study, randomly numbered all strains, including the 25
copies of the reference strain, thus ensuring that all tests
were performed in a blind fashion.
The antimicrobial susceptibilities to 16 antimicrobial agents
were determined for all isolates, using disk diffusion with
Oxoid disks on Iso-Sensitest agar (Oxoid, Basingsstoke, UK),
in accordance with the recommendations of the Swedish
Reference Group for Antibiotics (SRGA) [13]. All isolates
were tested against the following antimicrobial agents: ampicil-
lin, cefuroxime, cefpodoxime, chloramphenicol, ciproﬂoxacin,
fosfomycin–trometamol, gentamicin, imipenem, mecillinam,
nalidixic acid, nitrofurantoin, streptomycin, sulphamethoxaz-
ole, tetracycline, trimethoprim, and tigecycline. These were
selected to include agents commonly used to treat E. coli
infections and to represent different classes of antimicrobials.
The disk diffusion tests were performed at a single laboratory,
using a single batch of medium and plates. The zone diameters
were measured by two individuals.
MICs were determined using the Etest (AB Biodisk, Solna,
Sweden) on Mueller–Hinton agar (Becton-Dickinson, Franklin
Lakes, NJ, USA). MICs of four antimicrobial agents (ampicillin,
nalidixic acid, gentamicin, and trimethoprim) were determined
for all avian and clinical isolates. The Etests were performed at
a single laboratory, using a single batch of medium, and were
read by two individuals.
The characterization of wild-type IZD distributions was
performed using the NRI method as described by Kronvall
et al. [4,6]. This method is based on the assumption that iso-
lates of a deﬁned species carrying resistance mechanisms
exhibit smaller IZDs than isolates without resistance mecha-
nisms. The NRI cut off can be determined by calculating the
‘low equivalent’ of the mathematical ‘high-end’ of the suscep-
tible population [6]. The NRI analysis was applied to the
avian and clinical populations, respectively, and a separate
analysis was performed for the 25 replicates of E. coli strain
ATCC 25922.
Results
The antimicrobial susceptibilities of E. coli isolates of avian
(n = 97) and human (n = 100) origin and in 25 copies of the
reference strain E. coli ATCC 25922 were determined. For
each antimicrobial agent, IZD distributions, the median zone
diameter and an NRI-derived cut-off value were determined
for the three (avian, human and reference strain) distribu-
tions.
The avian and human IZD distributions of wild-type E. coli
were indistinguishable. The IZD distributions for four of the
agents tested are shown in Fig. 1. The medians of the wild-
type IZD distributions were in complete agreement for ten
of the antimicrobial agents, and differed by 1 mm in the
remaining cases (except for sulphamethoxazole, for which
the IZD distributions were irregular) (Table 1).
In order to validate the IZD distributions, the MICs of
four antimicrobial agents (ampicillin, gentamicin, nalidixic acid,
and trimethoprim) were determined for each avian and clini-
cal isolate, and MIC histograms were constructed. As previ-
ously observed for the IZD distributions, the avian and
human MIC distributions for wild-type E. coli were in excel-
lent agreement (Fig. 2). For the clinical population, the high-
est MIC value of the wild-type distribution was 4 mg/L for
ampicillin, 1 mg/L for gentamicin, 8 mg/L for nalidixic acid,
and 1 mg/L for trimethoprim (Fig. 2). For the avian popula-
tion, the highest MIC value of the wild-type distribution was
8 mg/L for ampicillin, 1 mg/L for gentamicin, 8 mg/L for nali-
dixic acid, and 1 mg/L for trimethoprim (Fig. 2). For a more
detailed discussion of the antimicrobial susceptibility patterns
and the potential sources of the resistance determinants
among the avian isolates, readers are referred to a previous
study [14].
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Discussion
In order to distinguish between isolates with and without
acquired or mutational resistance, EUCAST has determined
ECOFFs for a large number of microorganisms and drugs.
These are freely available on the EUCAST website (http://
www.eucast.org). The work of EUCAST has been, so far,
based on MIC data collected by numerous investigators and
from publications from all over the world. There are cur-
rently more than 17 000 MIC distributions in the database,
and it is constantly growing.
The ECOFFs make it possible to phenotypically detect
resistance in the most sensitive way. In addition, ECOFFs
can be employed in populations of bacteria from varying host
sources (humans, animal, and plants), thus bypassing the difﬁ-
culties of having to determine the relevance of different
breakpoints for treating infections [15–17]. However, a pre-
requisite for using the same ECOFF on isolates of different
origin is that the wild-type distributions are independent of
the host species.
To our knowledge, this is the ﬁrst report conﬁrming that
wild-type distributions of non-clinical and clinical isolates of
E . coli are indistinguishable for a large set of antimicrobial
agents. This has several implications. First, it conﬁrms the
usefulness and accuracy of studying wild-type distributions
when establishing breakpoints and cut-offs. Second, and most
importantly, it suggests that the same ECOFFs can be used
for resistance surveillance in both veterinary and human
medicine [15].
In the present study, the IZD distributions were validated
by determining the MIC distributions for a subset of the anti-
microbial agents investigated. As previously noted for the
IZD distributions, there was an overall agreement between
the human and avian MIC distributions. Furthermore, by
establishment of NRI-derived cut-off values deﬁning the wild-
type populations of the IZD distributions, and comparison of
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FIG. 1. Inhibition zone diameter histograms for clinical and avian isolates. The dashed line indicates the normalized resistance interpretation
(NRI)-derived cut-off value for the wild-type population as determined by the NRI method.
TABLE 1. Median and normalized resistance interpretation
(NRI)-derived cut-off values from inhibition zone diameter
(IZD) distributions (mm) of wild-type isolates
Median (mm) and NRI-derived cut-off
values (mm) from IZD distributions
of wild-type Escherichia coli isolatesa
Antimicrobial agent
(disk content, lg)
Clinical
isolates
(n = 100)
Avian
isolates
(n = 97)
ATCC
25922
(n = 25)
Ampicillin (10) 20/14 21/15 17/13
Cefpodoxime (10) 31/25 30/26 30/25
Cefuroxime (30) 25/20 25/19 25/21
Chloramphenicol (30) 26/18 26/19 27/23
Ciproﬂoxacin (5) 37/30 38/31 39/32
Fosfomycin (200) 32/26 32/24 32/27
Gentamicin (30) 27/24 27/23 28/24
Imipenem (10) 34/27 34/29 33/28
Mecillinam (10) 33/28 33/27 32/29
Nalidixic acid (30) 29/22 28/22 30/26
Nitrofurantoin (10) 24/17 23/17 24/21
Streptomycin (10) 20/17 20/17 20/ND
Sulphamethoxazole (100) 24/10b 26/10b 21/10b
Tetracycline (30) 28/23 28/22 28/25
Trimethoprim (5) 32/23 32/23 31/26
Tigecycline (15) 28/22 28/22 28/23
ND, not determined.
aWild-type distributions as deﬁned by the NRI method.
bOwing to irregular histogram distributions, the normalization procedure could
not be performed. The breakpoint for sulphamethoxazole was arbitrarily set to
R < 10 mm.
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these to the wild-type populations of the MIC distributions
(deﬁned by EUCAST ECOFFs), it was found that the numbers
of non-wild-type isolates were the same, irrespective of the
methodology. Thus, the NRI method can be used to establish
relevant cut-off values to deﬁne wild-type populations on the
basis of IZDs. However, unless the test system used has an
international standing, the cut-off value will be relative and
related to the collection of isolates studied. In the present
study, the IZDs are related to the AST methodology
described by SRGA and BSAC (IsoSensitest Agar (Oxoid);
semiconﬂuent growth) and the MIC to the CLSI’s recommen-
dations for Etests [13]. The MIC values in the EUCAST data-
base are based on CLSI and EUCAST broth dilution
techniques and Etests. Hopefully, all these methodologies will
be validated against the internationally standardized broth
dilution method [18,19]. If this was done, the ECOFFs deﬁned
by EUCAST could become internationally valid.
The highest MIC of a wild-type distribution should theo-
retically be equivalent to the ECOFF (mg/L) deﬁned by
EUCAST (http://www.eucast.org). For the four antimicrobial
agents investigated in this study, the MICs deﬁning the wild-
type distributions of the clinical isolates were all within one
dilution step of EUCAST’s suggested ECOFFs. For the avian
population, the MIC deﬁning the wild-type distribution for
ampicillin coincided completely with EUCAST’s suggested
ECOFF (8 mg/L) and was within one dilution step for the
remaining three antimicrobial agents tested (nalidixic acid,
gentamicin, and trimethoprim).
The exact same distributions as those of EUCAST were
not obtained, which is explained by the fact that the MIC
histograms were based on 100 isolates, whereas those of
EUCAST are based on many thousands of MIC values. The
difference in variation is obvious. Furthermore, the EUCAST
MIC distributions are collected from many investigators and
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FIG. 2. MIC histograms for clinical and avian isolates. The dashed line indicates the epidemiological cut-off values (ECOFFs) for the wild-type
distribution as determined by EUCAST (http://www.eucast.org). aTrimethoprim concentration test range: 0.016–32 mg/L.
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are based on several AST methodologies, whereas the pres-
ent data originated from a single laboratory using a single
method.
In summary, it is shown that wild-type distributions of
E. coli isolates originating from humans and wild birds are
identical. One of the authors, in conjunction with European
veterinarians, has compared similar data from many other
animal species while assembling the EUCAST database.
However, more studies comparing the wild-type distribu-
tions of isolates from different sources are warranted. The
present ﬁndings show that the same ECOFFs can be used
to deﬁne resistance in E. coli isolates, regardless of origin.
This is highly relevant for harmonization of breakpoints in
veterinary and human medicine, and it suggests a practical
way forward for globally harmonized surveillance of anti-
microbial resistance.
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